(Borneol + Edaravone) is a small molecule commercialized by Simcere Pharmaceutical Group, with a leading Phase I program in Acute Ischemic Stroke. According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of (Borneol + Edaravone)’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for (Borneol + Edaravone) is expected to reach an annual total of $4 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
(Borneol + Edaravone) Overview
Edaravone in combination with borneol (Y-2) is under development for the treatment of acute ischemic stroke, amyotrophic lateral sclerosis and acute hemorrhagic stroke. It acts by targeting free radical. The drug candidate is formulated as a tablet and administered through sublingual route.
Simcere Pharmaceutical Group Overview
Simcere Pharmaceutical Group (Simcere) is a pharmaceutical company discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas such as anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle, and others. Its product portfolio includes recombinant human endostatin injection, palonosetron hydrochloride injection, nedaplatin for injection, fluorouracil implants and lyvamlodipine besylate tablets, among others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low end generics and APIs to innovative medicines. The company’s precision medicine sector, Simcere diagnostics had strategic partnership t with Agena bioscience focused on Agena’s Massarray System for companion diagnostics and pharmacogenetic testing in China. Simcere is headquartered in Nanjing, Jiangsu, China
The company reported revenues of (Renminbi) CNY4,999.7 million for the fiscal year ended December 2021 (FY2021), an increase of 10.9% over FY2020. In FY2021, the company’s operating margin was 29%, compared to an operating margin of 20.6% in FY2020. In FY2021, the company recorded a net margin of 30.1%, compared to a net margin of 14.8% in FY2020.
For a complete picture of (Borneol + Edaravone)’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.